Study of Sodium Zirconium Cyclosilicate to Control Interdialytic Hyperkalemia Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fibrillation and Clinically Significant Cardiac Arrhythmias
Brief description of study
The aim of the study is to determine whether changing dialysis patients from a “standard” regimen (without Lokelma) to a different dialysis regimen including Lokelma, to treat high potassium during dialysis, will reduce the number of times a person has atrial fibrillation (an irregular quick heartbeat). Atrial fibrillation the most common form of irregular heartbeat after dialysis and can be observed in over 40% of dialysis patients.
Lokelma is approved for the treatment of high potassium in adults. Lokelma binds to potassium and lowers levels of potassium in the blood. Lokelma is experimental in this study, which means that it is not typically used in standard dialysis care.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
